# A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors

> **NCT06992713** · PHASE1 · RECRUITING · sponsor: **Shenzhen Hepalink Pharmaceutical Group Co., Ltd.** · enrollment: 36 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** H1710 for Injection

## Key facts

- **NCT ID:** NCT06992713
- **Lead sponsor:** Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-18
- **Primary completion:** 2026-09-04
- **Final completion:** 2026-11-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06992713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06992713, "A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06992713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*